Ads
related to: metolazone and kidney disease- Screening & Diagnosis
Learn About Screening &
Diagnosis Here.
- Dosing
Medication Dosing Information
For Healthcare Professionals.
- Resources
Discover Resources For You
And Your Patients.
- Savings & Access
Treatment Savings & Access
For Your Patients.
- Screening & Diagnosis
Search results
Results From The WOW.Com Content Network
Metolazone may be combined with other diuretics (typically loop diuretics) to treat diuretic resistance in congestive heart failure, chronic kidney disease, and nephrotic syndrome. [3] Metolazone and a loop diuretic will synergistically enhance diuresis over the use of either agent alone.
Patients with chronic kidney disease therefore require close monitoring when taking the drug. Spironolactone is also eliminated through feces (35-41%). The excretion of eplerenone is 67% through kidneys and 32% through feces.
Loop diuretics may also precipitate kidney failure in patients concurrently taking an NSAID and an ACE inhibitor—the so-called "triple whammy" effect. [19] Because furosemide, torsemide and bumetanide are technically sulfa drugs, there is a theoretical risk that patients sensitive to sulfonamides may be sensitive to these loop diuretics. This ...
Finerenone, marketed under the brand name Kerendia among others, is a medication used to reduce the risk of kidney function decline, kidney failure, cardiovascular death, non-fatal heart attacks, and hospitalization for heart failure in adults with chronic kidney disease associated with type 2 diabetes. [8]
Structural formula of the potassium-sparing diuretics. Click to enlarge. Potassium-sparing diuretics or antikaliuretics [1] refer to drugs that cause diuresis without causing potassium loss in the urine. [2]
A new study compares the benefits and risks of taking GLP-1 medications for weight loss, including risks of dementia, addiction, heart disease, and gastrointestinal problems, among others.
Ad
related to: metolazone and kidney disease